NEW YORK (Reuters Health) – The first experimental HIV vaccine, known as AIDS, has shown amazing immune responses to humans, according to a study.
The Lancet medical journal published a study showing that the experimental vaccine, developed by a team of researchers 40 years ago, began to show strong responses especially to monkeys, and managed to protect them from infection.
Novel #HIV vaccine candidate is safe and induces immune response in healthy adults and monkeys—results from an evaluation of a mosaic HIV-1 vaccine in a phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) https://t.co/vrYCEZMlSc pic.twitter.com/cYEICM2uo1
— The Lancet (@TheLancet) 6 juillet 2018
“So far, the vaccine has managed to protect two-thirds of the monkeys in a laboratory experiment, but that does not mean it will protect humans, so we need to wait for the results of the study before we know whether it will protect humans from AIDS,” he said.
The final results of the new AIDS vaccine are expected to occur between 2021 and 2022.
Study how Facilitated #DNA_inoculation induces anti-HIV-1 #immunity in vivo.#Infection #Inflammation #Allergy #Immunology #Immunogenetics #Molecular_Immunology #Immunotherapy #vaccine
Submit your abstracts at: https://t.co/JVprkYUAys
(Abstract submission deadline: June 30) pic.twitter.com/FAdcmPJ7u5
— Immunology World 2018 (@Emmawil91) 28 juin 2018
What is promising, however, is that the vaccine has shown “high levels of immune responses to humans, which may prove to be very effective in preventing AIDS.”
The study indicated that only five participants talked about side effects of the vaccine, such as stomach pain, diarrhea, dizziness or back pain.